Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
15
03
2024
accepted:
28
08
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.
Identifiants
pubmed: 39375508
doi: 10.1038/s41698-024-00685-9
pii: 10.1038/s41698-024-00685-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
227Informations de copyright
© 2024. The Author(s).
Références
Arkenau, H. T. et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br. J. Cancer 98, 1029–1033 (2008).
doi: 10.1038/sj.bjc.6604218
pubmed: 18349817
pmcid: 2275488
Arkenau, H. T. et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur. J. Cancer 44, 1536–1540 (2008).
doi: 10.1016/j.ejca.2008.04.017
pubmed: 18550361
Chau, N. G. et al. Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? BMC Cancer 11, 426 (2011).
doi: 10.1186/1471-2407-11-426
pubmed: 21975023
pmcid: 3199018
Bigot, F. et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur. J. Cancer 84, 212–218 (2017).
doi: 10.1016/j.ejca.2017.07.027
pubmed: 28826074
Rolfo, C. et al. Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J. Thorac. Oncol. 16, 1647–1662 (2021).
doi: 10.1016/j.jtho.2021.06.017
pubmed: 34246791
Keller, L., Belloum, Y., Wikman, H. & Pantel, K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br. J. Cancer 124, 345–358 (2021).
doi: 10.1038/s41416-020-01047-5
pubmed: 32968207
Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750–768 (2022).
doi: 10.1016/j.annonc.2022.05.520
pubmed: 35809752
Pessoa, L. S., Heringer, M. & Ferrer, V. P. ctDNA as a cancer biomarker: a broad overview. Crit. Rev. Oncol. Hematol. 155, 103109 (2020).
doi: 10.1016/j.critrevonc.2020.103109
pubmed: 33049662
Stover, D. G. et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J. Clin. Oncol. 36, 543–553 (2018).
doi: 10.1200/JCO.2017.76.0033
pubmed: 29298117
pmcid: 5815405
Kohli, M. et al. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine 54, 102728 (2020).
doi: 10.1016/j.ebiom.2020.102728
pubmed: 32268276
pmcid: 7186589
Choudhury, A. D. et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3, 122109 (2018).
doi: 10.1172/jci.insight.122109
pubmed: 30385733
Reichert, Z. R. et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. 34, 111–120 (2023).
doi: 10.1016/j.annonc.2022.09.163
pubmed: 36208697
Chakiba, C., Grellety, T., Bellera, C. & Italiano, A. Encouraging trends in modern phase 1 oncology trials. N. Engl. J. Med. 378, 2242–2243 (2018).
doi: 10.1056/NEJMc1803837
pubmed: 29874526
Italiano, A. Participation in phase 1 trials for patients with cancer. Lancet 400, 473–475 (2022).
doi: 10.1016/S0140-6736(22)01533-1
pubmed: 35964596
Chihara, D. et al. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet 400, 512–521 (2022).
doi: 10.1016/S0140-6736(22)01390-3
pubmed: 35964611
pmcid: 9477645
Schutte, K. et al. An artificial intelligence model predicts the survival of solid tumour patients from imaging and clinical data. Eur. J. Cancer Oxf. Engl. 1990 174, 90–98 (2022).